The European Federation of Pharmaceutical Industries and Associations (EFPIA), as part of a coalition of 35 large health stakeholder organizations representing patients, health professionals, researchers and industrial actors in the healthcare ecosystem at both European Union (EU) and member state level, is expressing its shared concerns about the latest negotiations on the proposed Regulation on the European Health Data Space (EHDS).
The EHDS is currently being negotiated at speed by EU institutions to get it ‘over the line’ before the end of this political term, the trade group noted in a website posting today.
There is a real desire by the health stakeholder community for this proposed legislation to be a success. The potential benefits offered by a well-functioning EHDS would be significant. The EHDS is intended to make the functioning of European health systems more efficient, contribute to better health outcomes, and support public health and health research and innovation activities in the EU.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze